Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | PLA2G4A | P47712 | 2/20 | 0.48 |
| ▸ | B3GNT2 | Q9NY97 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 5/20 | 0.47 |
| ▸ | HTR2A | P28223 | 4/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.45 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.43 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.43 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8553607 | 0.88 | B3GNT2 (0.50) | KDM4EPLA2G4AB3GNT2HTR2CHTR2A | |
| SCHEMBL698712 | 0.85 | HDAC8 (0.46) | PLA2G4AHTR2CHTR2AHDAC11HDAC8 | |
| SCHEMBL15971349 | 0.84 | KDM4E (0.55) | KDM4EHTR2CHTR2AHDAC11HDAC8 | |
| SCHEMBL9032942 | 0.84 | HTR2A (0.41) | HTR2CHTR2AHDAC11HDAC8HDAC6 | |
| SCHEMBL9032954 | 0.84 | HTR2A (0.41) | HTR2CHTR2AHDAC11HDAC8HDAC6 | |
| SCHEMBL5387474 | 0.83 | TUBB4A (0.59) | KDM4EPLA2G4AHDAC11HDAC8HDAC6 | |
| SCHEMBL5068315 | 0.81 | TUBB4A (0.57) | KDM4EPLA2G4AHDAC11HDAC8HDAC6 | |
| SCHEMBL4934703 | 0.80 | PLA2G4A (0.55) | PLA2G4ARAPGEF4 | |
| SCHEMBL15921713 | 0.80 | PLA2G4A (0.55) | KDM4EPLA2G4AHDAC11HDAC8HDAC6 | |
| SCHEMBL28607801 | 0.80 | KMT2A (0.60) | PLA2G4ARAPGEF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2958913-B1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT | LG CHEMICAL LTD (KR) | 2018-10-03 | — | — | EP | disclosed |
| US-9540362-B2 | Sphingosine-1-phosphate receptor agonists, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent | LG LIFE SCIENCES LTD. (KR) | 2017-01-10 | — | — | US | disclosed |
| EP-1595866-B1 | Cyanopyrrolidines useful for the treatment of inter alia metabolic syndrome | SANWA KAGAKU KENKYUSHO CO (JP) | 2016-06-08 | — | — | EP | disclosed |
| US-20150376173-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT | LG LIFE SCIENCES LTD. (KR) | 2015-12-31 | — | — | US | disclosed |
| EP-2958913-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT | LG Life Sciences Ltd. (KR) | 2015-12-30 | — | — | EP | disclosed |
| CN-105051037-A | Sphingosine-1-phosphate receptor agonists, method for the preparation thereof and pharmaceutical compositions comprising the same as active agent | LG LIFE SCIENCES LTD | 2015-11-11 | — | — | CN | disclosed |
| WO-2014129796-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT | LG LIFE SCIENCES LTD. (KR) | 2014-08-28 | — | — | WO | disclosed |
| CN-100434420-C | Compounds that block dipeptidyl peptidase IV | SANWA KAGAKU KENKYUSHO CO (JP) | 2008-11-19 | — | — | CN | disclosed |
| US-7345180-B2 | Compound inhibiting dipeptidyl peptidase IV | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2008-03-18 | — | — | US | disclosed |
| US-20060229286-A1 | Compound inhibiting dipeptidyl peptidase IV | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2006-10-12 | — | — | US | disclosed |
| CN-1745063-A | Compound inhibiting dipeptidyl peptidase iv | SANWA KAGAKU KENKYUSHO CO (JP) | 2006-03-08 | — | — | CN | disclosed |
| EP-1595866-A1 | COMPOUND INHIBITING DIPEPTIDYL PEPTIDASE IV | Sanwa Kagaku Kenkyusho Co., Ltd. (JP) | 2005-11-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376173-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT | S1PR1, S1PR2, S1PR5 | KDM4E 2290/4885PLA2G4A 178/4885B3GNT2 3247/4885 |
| US-20060229286-A1 | Compound inhibiting dipeptidyl peptidase IV | DPP4, DPP3, DPP7 | KDM4E 2352/4885PLA2G4A 4463/4885B3GNT2 872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.